Loss of Pulse Detection vs LINQ II Insertable Cardiac Monitor

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI Verdict

Fitbit's Loss of Pulse Detection and Medtronic's LINQ II Insertable Cardiac Monitor address distinct needs within cardiology AI. The Fitbit feature focuses on acute emergency response by detecting a potential loss of pulse and alerting services, while the Medtronic device provides long-term, continuous heart rhythm monitoring for diagnosing arrhythmias. Therefore, they are not direct competitors but rather adjacent tools serving different aspects of cardiac care.

Choose Loss of Pulse Detection if…

Choose Fitbit's Loss of Pulse Detection if you are an individual seeking an immediate, automated emergency response system for sudden, critical cardiac events. This feature is ideal for users who desire the peace of mind that comes with a wearable device capable of detecting a potential loss of pulse and automatically alerting emergency services if they become unresponsive, particularly when alone.

View Loss of Pulse Detection →

Choose LINQ II Insertable Cardiac Monitor if…

Choose the Medtronic LINQ II Insertable Cardiac Monitor if you are a clinician needing long-term, continuous heart rhythm monitoring for patients with suspected or diagnosed arrhythmias that are difficult to capture with external monitors. This device is best suited for diagnosing infrequent or asymptomatic arrhythmias over an extended period (up to 4.5 years) with enhanced AI-powered accuracy and remote management capabilities.

View LINQ II Insertable Cardiac Monitor →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Loss of Pulse Detection LINQ II Insertable Cardiac Monitor
Deployment Unknown Subcutaneous implant with remote monitoring via mobile app or home communicator.
BAA Available Yes AI-estimated Unknown
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Loss of Pulse Detection

Tool A (Loss of Pulse Detection) is integrated into a consumer wearable device, offering a non-invasive and automatic experience for the end-user. Tool B (LINQ II) requires a medical procedure for insertion, making its initial adoption less straightforward from a patient's perspective, despite its remote monitoring capabilities for clinicians.

Clinical Value

LINQ II Insertable Cardiac Monitor

Tool B (LINQ II) provides long-term, continuous heart rhythm monitoring with AI-powered accuracy for diagnosing a broader range of arrhythmias, including a pediatric indication, offering comprehensive diagnostic and management value over an extended period. Tool A focuses on acute, life-threatening loss of pulse events and emergency alerts, which is valuable but more reactive and limited in scope.

Pricing & Value

Loss of Pulse Detection

Tool A (Loss of Pulse Detection) is included with compatible Fitbit/Pixel devices and is not sold as a standalone subscription, offering clear and transparent value to the individual consumer. Tool B (LINQ II) has enterprise pricing that is negotiated with healthcare systems and not publicly disclosed, making its value proposition less transparent for the end-user.

Enterprise Readiness

LINQ II Insertable Cardiac Monitor

Tool B (LINQ II) is explicitly designed for healthcare systems, with a track record of over 1 million patients worldwide and features like remote programming and integration with the CareLink Network, demonstrating robust enterprise adoption and infrastructure. Tool A is a consumer-facing feature on a wearable, and while FDA-cleared and HIPAA-compliant, its primary deployment model is not directly enterprise-focused in the same way as an implantable cardiac monitor.

Innovation

LINQ II Insertable Cardiac Monitor

Tool B (LINQ II) showcases significant innovation with its AccuRhythmu2122 AI algorithms for enhanced accuracy, innovative PVC detection, and long-term continuous monitoring (up to 4.5 years), pushing the boundaries of implantable cardiac monitoring. Tool A's automatic loss of pulse detection and emergency calling on a wearable is innovative for a consumer device, but Tool B's AI-driven diagnostic advancements in a specialized medical device category represent a deeper technological leap.

Support & Docs

LINQ II Insertable Cardiac Monitor

As a medical device for healthcare systems, Medtronic (Tool B) provides extensive professional support, training, and comprehensive documentation for clinicians, including dedicated technical and patient services. Fitbit (Tool A), being a consumer feature, relies on general customer support channels and device manuals, which are typically less specialized and comprehensive than those for enterprise medical devices.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Loss of Pulse Detection LINQ II Insertable Cardiac Monitor
Company Fitbit Medtronic
Primary Detection/Monitoring Capability Automatic loss of pulse detection with emergency service alerts Long-term, continuous heart rhythm monitoring with AI-powered accuracy for diagnosing arrhythmias
Target Medical Specialties Cardiology, Critical Care, Emergency Medicine Cardiology
Long-term Monitoring Duration Not specified Up to 4.5 years
Pediatric Indication Not specified Yes (ages 2+)

Videos

Demos, reviews, and walkthroughs featuring Loss of Pulse Detection and LINQ II Insertable Cardiac Monitor.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Fitbit's Loss of Pulse Detection is an FDA-cleared feature designed to detect a potential loss of pulse and automatically alert emergency services if the user is unresponsive. The Medtronic LINQ II Insertable Cardiac Monitor is an FDA-cleared device providing long-term, continuous heart rhythm monitoring for diagnosing arrhythmias, including a pediatric indication for ages 2 and older.
Fitbit's Loss of Pulse Detection utilizes PPG and accelerometry sensors with an algorithm employing digital signal processing and machine learning (convolutional neural network) to detect a potential loss of pulse. The Medtronic LINQ II features AccuRhythmu2122 AI algorithms for enhanced accuracy in diagnosing arrhythmias, including reducing false alerts for atrial fibrillation and pause events, and an innovative PVC detection algorithm.
If a loss of pulse is detected and the user is unresponsive, Fitbit's Loss of Pulse Detection automatically alerts emergency services and shares the user's location. The Medtronic LINQ II transmits continuous heart rhythm data to healthcare providers via the MyCareLink Heartu2122 mobile app or the MyCareLink Relayu2122 home communicator.
Fitbit's Loss of Pulse Detection is an opt-in feature for users of compatible smartwatches, intended for over-the-counter use and not for individuals under 22 or those with pre-existing high risk for sudden cardiac death. The Medtronic LINQ II is indicated for adult and pediatric patients (ages 2+) with clinical syndromes or transient symptoms suggesting cardiac arrhythmias, requiring long-term monitoring.

Backers

Who funded each tool's parent company.

Loss of Pulse Detection

AI Tool Finder
AI-powered search. Results may not be comprehensive.